Drug Interactions between carbamazepine and Qulipta
This report displays the potential drug interactions for the following 2 drugs:
- carbamazepine
- Qulipta (atogepant)
Interactions between your drugs
carBAMazepine atogepant
Applies to: carbamazepine and Qulipta (atogepant)
ADJUST DOSE: Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of atogepant, which is primarily metabolized by the isoenzyme. When atogepant was administered in healthy study subjects with steady-state rifampin, a potent CYP450 3A4 inducer, atogepant peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 30% and 60%, respectively. No dedicated drug interaction studies were conducted to assess concomitant use with moderate CYP450 3A4 inducers, but reduced atogepant exposure would be expected.
MANAGEMENT: For the treatment of episodic migraine, the recommended dosage of atogepant is 30 mg or 60 mg once daily when used concomitantly with potent or moderate CYP450 3A4 inducers. For the treatment of chronic migraine, the manufacturer recommends avoiding concomitant use of atogepant with potent or moderate CYP450 3A4 inducers.
References (4)
- (2025) "Product Information. Aquipta (atogepant)." AbbVie Ltd
- (2025) "Product Information. Qulipta (atogepant)." AbbVie US LLC
- (2025) "Product Information. Qulipta (atogepant)." AbbVie Corporation
- (2023) "Product Information. Qulipta (atogepant)." AbbVie US LLC, 2
Drug and food/lifestyle interactions
carBAMazepine food/lifestyle
Applies to: carbamazepine
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of carbamazepine. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
In a small, randomized, crossover study, the administration of carbamazepine with grapefruit juice (compared to water) increased plasma drug concentrations by approximately 40%. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.
MANAGEMENT: Patients receiving carbamazepine should be advised to avoid or limit consumption of alcohol. Given the drug's narrow therapeutic index, patients receiving carbamazepine therapy should preferably avoid the regular consumption of grapefruits and grapefruit juice to prevent any undue fluctuations in plasma drug levels. Patients should be advised to report signs of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia) to their physicians.
References (3)
- (2002) "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals
- Garg SK, Kumar N, Bhargava VK, Prabhakar SK (1998) "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther, 64, p. 286-8
- Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR (2000) "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther, 68, p. 468-77
atogepant food/lifestyle
Applies to: Qulipta (atogepant)
MONITOR: Coadministration with grapefruit products or green tea, inhibitors of CYP450 3A4, may increase the plasma concentrations of atogepant, which is primarily metabolized by the isoenzyme. When atogepant was administered with the potent CYP450 3A4 inhibitor itraconazole in healthy study subjects, atogepant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.2- and 5.5-fold, respectively. However, moderate and weak inhibitors may interact to a much lesser extent. Population pharmacokinetic modeling has suggested that moderate (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) or weak (e.g., cimetidine, esomeprazole) CYP450 3A4 inhibitors may increase atogepant AUC by 1.7- and 1.1-fold, respectively. The changes in atogepant exposure when coadministered with moderate or weak CYP450 3A4 inhibitors are not expected to be clinically significant.
MANAGEMENT: Caution is advised for patients taking atogepant and consuming grapefruit products, large amounts of green tea beverages or green tea extract. Patients should be monitored for nausea, constipation, and fatigue.
References (3)
- (2025) "Product Information. Aquipta (atogepant)." AbbVie Ltd
- (2025) "Product Information. Qulipta (atogepant)." AbbVie US LLC
- (2025) "Product Information. Qulipta (atogepant)." AbbVie Corporation
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.